SAN DIEGO, CA and PORTLAND, OR--(Marketwire -03/05/12)- Medistem Inc. (Pinksheets: MEDS.PK - News), in partnership with its Russian licensee, ERCell, announced the signing of a letter of intent* to begin clinical trials using Medistem's Endometrial Regenerative Cells (ERC) stem cells for renal, lung and peripheral artery disease. Trials will be conducted in the … [Read more...]
Medistem Inc. to Add Kidney and Lung Failure to Clinical Trials of Endometrial Regenerative Cells (ERC) Stem Cells in Russia
March 5, 2012 By
Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical Trials
February 28, 2012 By
An Evening With Medistem, Inc. SAN DIEGO, CA and PORTLAND, OR--(Marketwire -02/28/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today its Annual "Evening with Medistem" Event will take place in Portland, Oregon on March 7th, 2012. The event is being hosted by Vladimir Zaharchook, Vice Chairman at Medistem, Inc., and will feature stem cell … [Read more...]
Medistem Initiates Collaboration With Chinese Conglomerate Aimed at Clinical Development of Endometrial Regenerative Cells for Critical Limb Ischemia
February 18, 2012 By
Shanghai Jia Fu Medical Apparatus Inc to Support Research in "Universal Donor" Stem Cell Drug SAN DIEGO, CA--(Marketwire -02/18/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today initiation of joint efforts with the Chinese conglomerate, Shanghai Jia Fu Medical Apparatus Inc, in developing the Endometrial Regenerative Cell (ERC) "universal donor" … [Read more...]
Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid Arthritis
February 8, 2012 By
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire -02/06/12)- Benitec Biopharma (ASX: BLT.AX - News) and Medistem (Pinksheets: MEDS.PK - News) announced today the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma's patented gene silencing technology applied to stem cell-derived immune system cells called dendritic cells. … [Read more...]
Medistem and ERCell Initiate Phase II RECOVER-ERC Heart Failure Trial
January 30, 2012 By
First Three Patients Successfully Treated With ERC Stem Cell Using Novel "Retrograde Procedure" SAN DIEGO, CA--(Marketwire -01/30/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) together with its Russian Licensee, ERCell LLC, announced successful dosing of 3 heart failure patients in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde … [Read more...]
Dr. Alan Lewis, Previous CEO of Juvenile Diabetes Research Foundation, Joins Medistem Advisory Board
January 24, 2012 By
30-Year Industry Veteran to Assist Adult Stem Cell Company in Strategic Positioning and Alliance Formation SAN DIEGO, CA--(Marketwire -01/24/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today appointment of Dr. Alan Lewis to the company's advisory board. Dr. Lewis spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice … [Read more...]
Medistem and Licensee ERCell Receive Russian Regulatory Approval for the RECOVER-ERC Trial
January 23, 2012 By
Dose Escalating, Double Blind, Placebo Controlled Universal Donor Stem Cell Trial for No-Option Heart Failure Patients to Be Conducted at Backulev Center SAN DIEGO, CA--(Marketwire -01/23/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) together with its Russian Licensee, ERCell LLC, have received approval to initiate the first double-blind, placebo controlled … [Read more...]
Medistem Inc. Annual Letter to Shareholders
December 31, 2011 By
SAN DIEGO, CA--(Marketwire -12/31/11)- Medistem Inc. (Pinksheets: MEDS.PK - News) today issues the following letter to shareholders. Dear Fellow Shareholders, The last year has been remarkable for Medistem: new investors, new collaborators, and an FDA approval. The FDA approval is for a 15 patient study investigating the safety and therapeutic effects of … [Read more...]
Entest BioMedical and RenovoCyte Begin Pilot Study of “Universal Donor” Stem Cell Treatment of Canine Osteoarthritis
November 18, 2011 By
SAN DIEGO, CA--(Marketwire -11/18/11)- Entest BioMedical Inc. (OTCQB: ENTB.PK - News) (Pinksheets: ENTB.PK - News) and RenovoCyte LLC today announced the treatment of the first canine patient of a 10 dog pilot study utilizing Canine Endometrial Regenerative Cells (CERC) licensed from Medistem Inc. (Pinksheets: MEDS.PK - News) in the treatment of canine … [Read more...]
Yale Endometrial Stem Cell Expert Joins Medistem’s Scientific Advisory Board
November 8, 2011 By
SAN DIEGO, CA--(Marketwire -11/08/11)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today the appointment of Dr. Hugh S. Taylor to its Scientific Advisory Board. Dr. Taylor is the first scientist to identify the bone marrow origin of endometrial tissue, and performed independent experiments demonstrating that endometrial stem cells are capable of treating … [Read more...]